454 related articles for article (PubMed ID: 10670246)
1. [Effects of infusion treatment once a day for 4 weeks with alprostadil-alpha-cyclodextrin on blood levels of endothelin-1 in patients with chronic obliterative arteriopathy of the legs at Leriche-Fontaine stage 2].
Mangiafico RA; Malatino LS; Attinà T; Dell'Arte S; Messina R
Minerva Cardioangiol; 1999 Dec; 47(12):652-3. PubMed ID: 10670246
[No Abstract] [Full Text] [Related]
2. [Medical treatment of peripheral arteriopathies with alprostadil-alpha-cyclodextrin. Comparative analysis at national level of the expense/reimbursement ratio].
Mondani P; Agus GB
Minerva Cardioangiol; 1999 Dec; 47(12):660-1. PubMed ID: 10670250
[No Abstract] [Full Text] [Related]
3. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
4. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
5. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between hyperhomocysteinemia and endothelial activation in patients with obliterative arteriopathy of the legs].
Rogolino A; Farsi A; Brunelli T; Ilari I; Capanni M; Domeneghetti MP; Dorigo W; Lombardi R; Pulli R; Pratesi C; Gensini GF
Minerva Cardioangiol; 1999 Dec; 47(12):583. PubMed ID: 10670214
[No Abstract] [Full Text] [Related]
7. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
Rudofsky G
Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
[No Abstract] [Full Text] [Related]
8. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
Gianetti J; De Caterina M; De Cristofaro T; Ungaro B; Guercio RD; De Caterina R
Am Heart J; 2001 Oct; 142(4):733-9. PubMed ID: 11579367
[TBL] [Abstract][Full Text] [Related]
9. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
[TBL] [Abstract][Full Text] [Related]
10. A new surgical approach to vasodilating therapy in peripheral occlusive vascular disease.
Horch R; Krönung G
Nihon Geka Hokan; 1988 Nov; 57(6):487-92. PubMed ID: 3268061
[No Abstract] [Full Text] [Related]
11. [Duplex ultrasound measurement of hemodynamic parameters at rest and following arterial stenosis: effect of intra-arterial infusion therapy with prostaglandin E1].
Ranke C; Creutzig A; Alexander K
Vasa Suppl; 1989; 27():353-5. PubMed ID: 2696104
[No Abstract] [Full Text] [Related]
12. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
[TBL] [Abstract][Full Text] [Related]
13. Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb.
Mangiafico RA; Malatino LS; Spada RS; Santonocito M; Messina R; Dell'Arte S; Attinà T
Int Angiol; 2000 Mar; 19(1):14-7. PubMed ID: 10853680
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
Balzer K; Rogatti W; Rüttgerodt K
Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
[TBL] [Abstract][Full Text] [Related]
15. [Prostaglandin E1 in intermittent claudication].
Scheffler P; de la Hamette D; Rogatti W
Vasa Suppl; 1992; 35():147-8. PubMed ID: 1481022
[No Abstract] [Full Text] [Related]
16. Homocysteine and vascular diseases.
Marasini B; Massarotti M; Biondi ML
Circulation; 2002 Aug; 106(7):e33. PubMed ID: 12176969
[No Abstract] [Full Text] [Related]
17. [Treatment with mesoglycan of chronic obliterative atherosclerotic arteriopathies of the legs. Hematochemical and flowmetric changes].
di Giovanna VN
Clin Ter; 1988 Jun; 125(6):431-4. PubMed ID: 2973949
[No Abstract] [Full Text] [Related]
18. [Intravenous administration of PGE1: studies of the effectiveness and duration of the effect of various dosages based on flow measurements of the femoral artery in patients with healthy vessels and in stage IIb arterial occlusive disease].
Scheffler P; Birkel L; Grub KR; de la Hamette D
Vasa Suppl; 1988; 23():126-9. PubMed ID: 3061035
[No Abstract] [Full Text] [Related]
19. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs.
Jagroop IA; Berwanger CS; Stansby G; Mikhailidis DP
Int Angiol; 1999 Mar; 18(1):77-9. PubMed ID: 10392486
[No Abstract] [Full Text] [Related]
20. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Attinà A; Sottilotta G; Canobbio V; Soraci S; Barbera N
Minerva Cardioangiol; 1999 Mar; 47(3):55-8. PubMed ID: 10389444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
